This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts initiated coverage on several major companies, including Amazon, Alphabet, Cardlytics, MercadoLibre, and Nurix Therapeutics, with varying ratings and price targets. Amazon received a Buy rating with a $260 target, while Alphabet was rated Sector Outperform with a $212 target.
October 11, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Evercore ISI Group initiated coverage on Cardlytics with an In-Line rating and a $4 price target, indicating a neutral outlook.
The In-Line rating and a price target of $4 suggest a neutral stance from the analyst, which may not significantly impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Pivotal Research initiated coverage on Amazon with a Buy rating and a $260 price target, indicating a positive outlook.
The initiation of coverage with a Buy rating and a significant price target of $260 suggests a strong positive sentiment from the analyst, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Scotiabank initiated coverage on Alphabet with a Sector Outperform rating and a $212 price target, suggesting a favorable outlook.
The Sector Outperform rating and a price target of $212 indicate a positive view from the analyst, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Redburn Atlantic initiated coverage on MercadoLibre with a Buy rating and a $2800 price target, indicating a strong positive outlook.
The Buy rating and a high price target of $2800 reflect a very positive view from the analyst, likely to attract investor interest and potentially drive the stock price up.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Jefferies initiated coverage on Nurix Therapeutics with a Buy rating and a $41 price target, suggesting a positive outlook.
The Buy rating and a price target of $41 indicate a positive sentiment from the analyst, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100